Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Moreau, Philippe
Chanan-Khan, Asher Alban Akmal
Roberts, Andrew Warwick
Agarwal, Amit
Facon, Thierry
Kumar, Shaji
Touzeau, Cyrille
Diehl, Susan
Cordero, Jaclyn
Ross, Jeremy A.
Munasinghe, Wijith
Zhu, Ming
Salem, Ahmed H.
Leverson, Joel
Maciag, Paulo Cesar
Verdugo, Maria E.
Harrison, Simon J.
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin Florida, Jacksonville, FL USA
[3] Royal Melbourne Hosp, Parkville, Vic, Australia
[4] Univ Arizona, Tucson, AZ USA
[5] CHRU Lille, Hop Claude Huriez, Lille, France
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] AbbVie Inc, N Chicago, IL USA
[8] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supp1.8011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
  • [23] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [24] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [25] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
  • [26] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [27] Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Harrison, Simon
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania T. M.
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Gay, Francesca
    Mikala, Gabor
    Punnoose, Elizabeth A.
    Hong, Wan-Jen
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Ward, James E.
    Maciag, Paulo C.
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [28] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Mark, Tomer Martin
    Rodriguez, Melissa
    Shah, Manan
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
    Bueno, Orlando
    Slimp, Rachel
    Jacobson, Michelle
    Pesko, John Carl
    Li, Hong
    Ross, Jeremy A.
    Freise, Kevin
    Maciag, Paulo Cesar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Reeder, Craig B.
    Roy, Vivek
    Halvorson, Alese E.
    Buadi, Francis
    Gertz, Morie A.
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Thompson, Melanie A.
    Crawley, Jamie
    Kapoor, Prashant
    Mikhael, Joseph
    Stewart, Keith
    Hayman, Suzanne R.
    Hwa, Yi L.
    Gonsalves, Wilson
    Witzig, Thomas E.
    Ailawadhi, Sikander
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Rivera, Candido E.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2016, 128 (20) : 2415 - 2422
12345